MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics Post published:January 5, 2024 Post category:Analysis/News
atai Life Sciences Makes $50m Investment in Beckley Psytech Post published:January 4, 2024 Post category:Analysis/News
Kentucky’s $42m Ibogaine Funding Appears Dead in the Water Post published:December 29, 2023 Post category:Analysis/News
BREAKING: MAPS PBC Files New Drug Application for MDMA-Assisted Therapy for PTSD Post published:December 12, 2023 Post category:Analysis/News
Pα+: A Nue Lease of Life? Beckley Waves Acquires Struggling At-Home Ketamine Provider Nue Life Health Post published:November 10, 2023 Post category:Analysis/News/Pα+
Pα+: MEP Action Group Meets in Brussels to Discuss Regulatory Pathways for Psychedelics Post published:November 8, 2023 Post category:Analysis/News/Pα+
MEP Action Group Meets in Brussels to Discuss Regulatory Pathways for Psychedelics Post published:November 8, 2023 Post category:Analysis/News
Cybin Shares Positive Interim Topline Data for Deuterated Psilocybin Analog Candidate Post published:October 31, 2023 Post category:Analysis/News
Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application Post published:September 14, 2023 Post category:News